









Markets
/
Stocks
/
nasdaq-uncy
/

Unicycive Therapeutics Inc

UNCY

View Detailed Chart

6.340USD

+5.672+849.81%

Close 06/20, 16:00（ET）Quotes delayed by 15 min

759.21MMarket Cap

LossP/E TTM



Unicycive Therapeutics Inc

6.340

+5.672+849.81%

Company

Intraday

30m

Today

+849.81%

5 Days

+830.44%

1 Month

+956.67%

6 Months

+826.90%

Year to Date

+698.29%

1 Year

+906.35%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

BUY

Current Rating

57.143

Target Price

8460.73%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

557

Total

Median

Average

Company name

Ratings

Analysts

Unicycive Therapeutics Inc

UNCY

Exact Sciences Corp

EXAS

CRISPR Therapeutics AG

CRSP

Regeneron Pharmaceuticals Inc

REGN

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

...

112

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(0)

Neutral(0)

Buy(0)

Indicators

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

RSI(14)

STOCH(KDJ)(9,3,3)

ATR(14)

CCI(14)

Williams %R

TRIX(12,20)

StochRSI(14)

Moving Average

Sell(0)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

News

More news coming soon, stay tuned...

Company

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Ticker SymbolUNCY

CompanyUnicycive Therapeutics Inc

CEODr. Shalabh Gupta, M.D.

Websitehttps://unicycive.com/